Results

Figure 2 provides an overview of the flow of the participants in the study. In total, 105 patients were included, of which 87 completed follow-up. The study population was composed of two sub-groups: care home residents (31%) and community-dwelling patients with chronic diseases (69%). During the intervention period, 18 patients were lost to follow-up for various reasons.
Eight care home residents were lost to follow-up. Four of them died before follow-up. By clinical evaluation, it was concluded that none of the deaths were directly related to the medication review intervention (e.g., one of the residents died from/with COVID-19). Other four patients were unable to collaborate on follow-up questionnaires. None of the included patients were admitted to the hospital between inclusion and follow-up.
Ten community-dwelling patients were lost to follow-up; five did not show up for the consultation and for five other patients, the follow-up questionnaire data was not collected for unspecified reasons. Four of the 60 included patients were admitted to the hospital during the intervention period. By clinical evaluation, it was concluded that none of the admissions were directly related to the medication review intervention.
Baseline characteristics of the total study population and the two sub-groups are provided in Table 1.